Captisol is the Key
Ligand Views $36.3M CyDex Acquisition as 'Game Changer'
By Tom Wall
Friday, January 28, 2011
Although its $36.3-million acquisition of privately held CyDex Pharmaceuticals Inc., of Lenexa, Kan., is the fourth in the last 28 months for Ligand Pharmaceuticals Inc., CEO John Higgins described it as "transformational" and a "game changer."
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.